Home >> Research Area >> Angiogenesis

Angiogenesis

Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels. In precise usage this is distinct from vasculogenesis, which is the de novo formation of endothelial cells from mesoderm cell precursors, and from neovascularization, although discussions are not always precise (especially in older texts). The first vessels in the developing embryo form through vasculogenesis, after which angiogenesis is responsible for most, if not all, blood vessel growth during development and in disease.

Products for Angiogenesis

Cat.No. Product Name Information
BCC5125 Btk inhibitor 1 R enantiomer IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
BCC3952 AC 264613 PAR₂ receptor agonist
BCC7089 Combretastatin A4 Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.
BCC3644 DMXAA (Vadimezan) Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan has anti-influenza virus H1N1-PR8 activities.
BCC1385 AVL-292 Spebrutinib (AVL-292; CC-292) is a covalent, orally active, and highly selective with an IC50 of 0.5 nM.
BCC4394 CNX-774 CNX-774 is a potent, selective, and orally available small molecule inhibitor of Btk (IC50< 1 nM) that forms a ligand-directed covalent bond with Cys-481, a non-conserved amino acid within the active site of the enzyme.
BCC6229 LDV FITC
BCC6998 GR 144053 trihydrochloride
BCC4131 BAY 87-2243 BAY 87-2243 is a highly potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor.
BCC3921 RN486 RN486 is a selective Btk inhibitor with an IC50 Value of 4.0 nM.
BCC6463 ONO-4059 ONO-4059 analog is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor.
BCC3950 Thrombin Receptor Agonist Peptide Sfllrnpndkyepf is a synthetic thrombin receptor agonist peptide.
BCC3957 TRAP-6 TRAP-6 (PAR-1 agonist peptide) is a protease-activated receptor 1 (PAR1) agonist.
BCC4238 Btk inhibitor 1 (Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
BCC3920 QL47 QL47 is a potent, selective and irreversible BTK kinase inhibitor with IC50 of 7 nM.
BCC5988 Echistatin, α1 isoform
BCC5548 CWHM-12 CWHM-12 is a potent inhibitor of αV integrins with IC₅₀s of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1.
BCC3590 Cyclo (-RGDfK) Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM.
BCC3947 SLIGRL-NH2 Protease-Activated Receptor-2 Activating Peptide is an agonist of Protease-Activated Receptor-2 (PAR-2).
BCC3945 BIO 1211 Selective α₄β₁ (VLA-4) inhibitor
BCC3942 Cilengitide Cilengitide, a cyclic RGD-containing peptide, is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50s of 4 and 79 nM, respectively.
BCC3959 SLIGKV-NH2 Protease-Activated Receptor-2, amide (SLIGKV-NH2) is a highly potent protease-activated receptor-2 (PAR2) activating peptide.
BCC3948 TFLLR-NH2 TFLLR-NH2 is a selective PAR1 agonist with an EC50 of 1.9 μM.
BCC6501 SB273005
BCC6402 FG2216 FG-2216 (IOX3; YM311) is a potent HIF-prolyl hydroxylase inhibitor with IC50 of 3.9 uM for PDH2 enzyme; orally bioavailable and induced significant and reversible Epo induction in vivo.
BCC3956 PAR 4 (1-6)
BCC4266 TR-14035 TR-14035 is a a dual alpha4beta7(IC50=7 nM)/alpha4beta1 (IC50=87 nM) integrin antagonist .
BCC6472 LFM-A13 LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.
BCC3955 LRGILS-NH2
BCC3944 A 205804 A-205804 is an orally bioavailable, potent and selective lead inhibitor of E-selectin and ICAM-1 expression, with an IC50 of 20 nM and 25 nM for E-selectin and ICAM-1, respectively. A-205804 can be used in the research of chronic inflammatory diseases.
BCC3946 A 286982 Potent inhibitor of the LFA-1/ICAM-1 interaction
BCC6080 TCS 2314 TCS 2314 (compound 3) is orally active and selective very late antigen-4 (VLA-4, α4β1, CD49d/CD29) antagonist with an IC50 of 4.4 nM.
BCC8002 BIO 5192
BCC4100 PCI 29732 PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
BCC6332 Leukadherin 1 Leukadherin-1 is a specific agonist of complement receptor 3 (CR3) and the leukocyte surface αMβ2 integrin CD11b/CD18.
BCC3949 AY-NH2 PAR-4 Agonist Peptide, amide (PAR-4-AP; AY-NH2) is a proteinase-activated receptor-4 (PAR-4) agonist, which has no effect on either PAR-1 or PAR-2 and whose effects are blocked by a PAR-4 antagonist.
BCC1575 Firategrast Firategrast is an orally bioavailable α4β1/α4β7 integrin antagonist.
BCC3642 ML161 Parmodulin 2 (ML161) is an allosteric inhibitor of protease-activated receptor 1 (PAR1) with an IC50 of 0.26 μM. Parmodulin 2 is a potent and non-competitive inhibitor of SFLLRN-induced P-selectin expression leading to inhibition of platelet aggregation in vitro and platelet thrombus formation in vivo.
BCC3954 RLLFT-NH2
BCC2070 Zaurategrast Zaurategrast (CT7758) is a potent and oral-effective α4-integrin inhibitor.
BCC5094 Plinabulin (NPI-2358) Plinabulin (NPI-2358) is a vascular disrupting agen (VDA) against tubulin-depolymerizing with an IC50 of 9.8 nM against HT-29 cells. Plinabulin binds the colchicine binding site of β-tubulin preventing polymerization and has potent inhibitory to tumor cells.
BCC3958 2-Furoyl-LIGRLO-amide 2-Furoyl-LIGRLO-amide is a potent and selective proteinase-activated receptor 2 (PAR2) agonist with a pD2 value of 7.0..
BCC2227 FG-4592 (ASP1517) Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin.
BCC6275 P11
BCC7458 OGT 2115 OGT 2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC50 of 0.4 μM. OGT 2115 has anti-angiogenic properties (IC50 of 1 μM). OGT 2115 also inhibits heparan sulfate degradation activity.
BCC1473 CGI-1746 CGI-1746 is a potent and highly selective inhibitor of the Btk with IC50 of 1.9 nM.
BCC7694 RGDS peptide Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function, decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS and MMP-9.
BCC3951 AC 55541 AC-55541 is a highly selective protease-activated receptor 2 (PAR2) agonist (pEC50=6.7), displays no activity at other PAR subtypes or at over 30 other receptors involved in nociception and inflammation. AC-55541 has pEC50 values of 5.9 and 6.6 in PI hydrolysis assays and Ca2+ mobilization assays and exhibits pronociceptive activity in vivo.
BCC6216 TC-I 15
BCC2229 IOX2(Glycine) IOX2 is a specific prolyl hydroxylase-2 (PHD2) inhibitor with IC50 of 22 nM.
BCC5124 PCI-32765 Racemate Ibrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM.
BCC1266 PCI-32765 (Ibrutinib) Ibrutinib (PCI-32765) is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM. Ibrutinib can be used as a Btk ligand in the synthesis of a series of PROTACs, such as P13I. P13I induces 73% degradation of Btk at 10 nM and 89% at 100 nM in human Burkitt’s lymphoma, RAMOS cells.
BCC3953 VKGILS-NH2 Control peptide for SLIGKV-NH₂
BCC5349 RGD (Arg-Gly-Asp) Peptides RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.